How to Open Your FREE DEMAT Account
The global pharmaceutical industry represents a robust ₹132,972,000 million market in 2024, projected to reach ₹176,400,000-184,800,000 million by 2029 at a CAGR of 5.5-6.5%, driven by aging populations, rising chronic diseases, and increased R&D investments. Cumulative pharmaceutical capex totalled ₹31,080,000-35,280,000 million during 2020-2024, maintaining 5-6% of industry revenue, with emerging markets like Asia-Pacific and Latin America demonstrating higher capex intensity compared to mature markets. Global pharmaceutical capex is estimated to grow 1.3x to ₹42,000,000-46,200,000 million between 2025-2029, fueled by patent expirations, generic medicine adoption, and pricing pressures necessitating sustained infrastructure investments. The MEA region specifically witnessed ₹756,000-840,000 million in pharmaceutical capex during 2020-2024, expected to increase 1.3x to ₹966,000-1,050,000 million over 2025-2029, as governments focus on pharmaceutical localization and self-reliance, creating substantial opportunities for turnkey engineering solution providers specializing in pharmaceutical manufacturing infrastructure development across emerging economies.
| Detail | Information |
|---|---|
| IPO Open Date | Sep 29, 2025 |
| IPO Close Date | Oct 01, 2025 |
| Price Band | ₹181– ₹191 per share |
| Lot Size | 75 shares |
| Issue Size | ₹2,303 million |
| Listing At | BSE, NSE |
| Tentative Listing Date | To be announced |
Fabtech Technologies Limited is a global turnkey engineering solutions provider specializing in pharmaceuticals, biotech, and healthcare facilities. With operations spanning over 62 countries across Middle East, Africa, Asia, Europe, Latin America, and North America, the company offers comprehensive solutions covering bio clean air, clean water, and process systems, supported by 94 qualified engineers and ISO-certified quality standards. Since incorporation, Fabtech has successfully completed 51 projects across countries including Saudi Arabia, Egypt, Algeria, Bangladesh, Ethiopia, Sri Lanka, and UAE. Operating through an asset-light model with a strong order book of ₹904.42 million as of July 31, 2025, Fabtech continues to demonstrate robust growth in emerging economies’ pharmaceutical infrastructure development.
Fabtech Technologies Limited demonstrated strong financial performance, with revenue from operations growing at an impressive CAGR of 29.83% over FY23-FY25 to reach ₹3,266.7 million in FY25, up from ₹1,938.0 million in FY23, reflecting the company’s robust execution capabilities in the global pharmaceuticals turnkey engineering solutions market. The company achieved substantial profitability enhancement with PAT growing at an exceptional CAGR of 46.20% from ₹217.3 million in FY23 to ₹464.5 million in FY25, translating to a significant improvement in PAT margin from 10.9% to 13.8%, showcasing the company’s ability to translate revenue growth into enhanced bottom-line profitability. The company maintained healthy return ratios with ROE improving from 27.8% to 30.5% and maintaining strong balance sheet metrics with debt-to-equity ratio at 0.32x and current ratio of 1.37x in FY25, while EBITDA remained robust at ₹472.8 million (14.1% margin), highlighting Fabtech’s strong operational efficiency and financial management in executing turnkey projects across 62+ countries in the rapidly expanding global pharmaceutical infrastructure development sector.
Objects of the issue:
- Funding working capital requirements of the company: ₹127.00 million
- Pursuing inorganic growth initiatives through acquisitions: ₹30.00 million
- General corporate purposes
📱 Apply Online through the SMIFS ELITE App | Download now:
Experience seamless investing at your fingertips!
